Podcasts about DRS

As healthcare policy debates resurface across the country, this rerun takes listeners back to a foundational question: what does it actually mean to call healthcare a human right? Drs. May and Tim Hindmarsh examine Oregon's decision to enshrine access to healthcare in its constitution and explore the practical implications behind the promise. Rather than debating ideals in the abstract, they focus on the real-world consequences—how rights-based language collides with limited resources, clinical judgment, and physician autonomy. It's a timely reminder that the words we use in healthcare policy carry weight, especially when they shape expectations for patients and doctors alike.GET SOCIAL WITH US!

Zondag 14 december Gij en ik (Van Maasakkers) Gerard van Maasakkers 4'00 Van de cd Zicht Cup 8033 Waar is de zon (C. van Doesburgh/E. Schimscheimer) Willeke Alberti 4'25 Van de cd Live in Carré DNCD 1480 Die lucht (P. Lusse/D. Kuys) Peter Lusse 3'23 Eigen opname De klacht van een agent (L. Valkenier/B. Stoots) Hans Otjes 3'22 van de LP Hé, kijk mij nou Bovema 5N 062 26038 Gebabbel G. Ferrio/M. Choisso/Giancarlo de Re/(C. Nooteboom) Ramses Shaffy & Liesbeth List 4'30 Eigen opname Appelmoes (Krijger) Jaap Krijger 3'09 Eigen opname Evenveel (H. v. Veen/H. v. Veen, E. Leerkes) Herman van Veen en Simone Kleinsma 2'44 Van de cd Plus Universal 787 739-1 Botanisch twistgesprek (Drs. P/R. v. Houten) Erik van Muiswinkel 3'38 Eigen opname Sneeuwblind (Jan en Kees Groenteman) Cast 3'07 uit musical Wintersprookje Eigen opname De Hoeksema's (A. M.G. Schmidt/H. Beuker) Emmy Arbous 4'18 Van de cd Ik zou je het liefste in een doosje willen doen NN 500.007-2 Frans is terug (M. v. Dijk, T. Maas/T. Maas) Thijs Maas 3'45 Van de cd Studio Eigen beheer Misstap (A. Nijgh/L. Nijgh) Astrid Nijgh 3'09 Van de cd Ik zou je liefste in een doosje willen doen NN 500.006-2

“Send us a Hey Now!”It's the end of the season so before we hang up our microphones for 2025 we need to give out our end of season awards.We also have a bumper crop of stats to take a look at as we look back at the season that was 2025.Episode running order as always is...1) News & SocialAll the best bits from both the sports news out there as well as what caught our eye on the various social channels2) Brian's Video Vault         https://www.youtube.com/watch?v=mqxYSbtDTrw&pp=0gcJCSkKAYcqIYzv. Alex Albon Reviews the Komatsu PC238 Excavator! Atlassian Williams Racing. 7 mins.https://youtu.be/DVFjIVikz9g?si=B82maoAQdqKeW9Qj. Working 9 to drive, ep 2. Visa CashApp RB channel. 5 mins.https://www.youtube.com/watch?v=wbWbUcRortI. The F1 Rookies' Season Review! Formula 1 channel. 13 mins. https://youtu.be/IC-OoENFVMc?si=JgpOEMtJQwZ3m_Bw. First Sakura | VF-25 Gets A New Look For The Japanese GP

Send us a textA calmer patient isn't just a kinder visit—it's a safer workplace. We sit down with researchers Drs. Gene Pavlovsky and Ellen Everett to unpack new data showing that veterinary teams see decreases in bites and scratches when every staff member completes low-stress handling certification. Partial participation helped culture in pockets, but it didn't move the needle on injuries. The lesson is clear: safety is a system, not a solo skill.We trace where stress truly starts, from the parking lot to the waiting room, and why early moments—carrier handling, first touch, body language checks—set the tone for the entire appointment. Gene and Ellen explain how teams identified high-risk scenarios and compare practices that rely on pre-visit medications or sedation to those built on consistent, low-stress workflows. The surprise? More drugs alone did not equal fewer injuries. Instead, shared training and peer accountability turned the tide: a receptionist who redirects a nervous dog to a quiet space, a certified veterinary technician who swaps scruffing for treats and positioning, and a veterinarian who uses “drive-by” sedation for severely fearful patients.Along the way, we challenge a stubborn myth that heavier restraint makes staff safer. Data and lived experience point the other way—restraint escalates fear, and fear drives defensive aggression. We talk practical tools like Churu for cats, environmental tweaks, and stepwise protocols that protect staff while preserving patient welfare. We also cover the business case: fewer missed days, lower workers' comp exposure, smoother procedures, and clients who notice the difference and come back.If you lead a small animal practice, teach vet students, or simply want better outcomes without bruises or burned-out teams, this conversation maps a path from intention to implementation. Subscribe, share with your team, and leave a rating and review—then tell us what's helped your hospital make low-stress care the norm.JAVMA article: https://doi.org/10.2460/javma.25.05.0325INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ® OR AJVR ® ? JAVMA ® : https://avma.org/JAVMAAuthors AJVR ® : https://avma.org/AJVRAuthorsFOLLOW US:JAVMA ® : Facebook: Journal of the American Veterinary Medical Association - JAVMA | Facebook Instagram: JAVMA (@avma_javma) • Instagram photos and videos Twitter: JAVMA (@AVMAJAVMA) / Twitter AJVR ® : Facebook: American Journal of Veterinary Research - AJVR | Facebook Instagram: AJVR (@ajvroa) • Instagram photos and videos Twitter: AJVR (@AJVROA) / Twitter JAVMA ® and AJVR ® LinkedIn: https://linkedin.com/company/avma-journals

Why might the standard RECIST criteria fail to accurately track success after tumor ablation, and what should you look for instead? In the 4th installment of the 2025 NSCLC Creator Weekend™ series, hosts Drs. Scott Genshaft and Kavi Krishnasamy are joined by specialists from UCLA and USC to discuss and debate advanced treatment options for primary lung cancer. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS The panel, including interventional radiologists, pulmonologists, and a radiation oncologist, discusses the intricacies of photon versus proton therapies, the physics behind radiation treatment, and the evolving landscape of ablation technologies. The conversation covers the efficacy and limitations of different treatments, patient selection criteria, and the role of newer technologies like electroporation and robotic-assisted bronchoscopy in enhancing precision and outcomes. Additionally, the panel addresses the practical challenges of intraprocedural imaging, the importance of adequate margins, and the complexities of managing local recurrences and radiation-induced toxicities. --- TIMESTAMPS 00:00 - Tumor Ablation and Recurrence Rates12:53 - Advancements in Ablation Technologies23:31 - Bronchoscopic Approaches in Lung Cancer Treatment38:46 - Challenges in Radiation Dose and Delivery49:21 - Ablation and Radiation Margins01:07:19 - Final Thoughts --- RESOURCES Thierry de Baere Paper on Ablation Margins https://pmc.ncbi.nlm.nih.gov/articles/PMC9815739/

Drs. Dan Ackerman, Valérie Biousse, and Nancy J. Newman discuss the clinical presentations, diagnostic challenges, and the importance of accurate diagnosis in managing CRAO and BRAO.  Show citation: Bénard-Séguin É, Nahab F, Pendley AM, et al. Eye stroke protocol in in the emergency department. J Stroke Cerebrovasc Dis. 2024;33(9):107895. doi:10.1016/j.jstrokecerebrovasdis.2024.107895 

Dean's Chat hosts, Drs. Jensen and Richey, welcome Dr. Devon Glazer to the Podcast! This episode is sponsored by the American Podiatric Medical Association (APMA)! Dr. Devon Glazer, DPM, from Los Angeles, is a board-certified podiatric physician specializing in the medical and surgical care of foot and ankle disorders. Known for his strong fellowship program, his patient-centered approach and contemporary use of evidence-based medicine, Dr. Glazer combines precision, compassion, and innovation to help patients regain mobility and improve quality of life. Dr. Glazer completed his doctoral training in podiatric medicine followed by rigorous clinical residency training in foot and ankle surgery. He trained on the East Coast and this benefited his transition to Califonia! His clinical interests include sports injuries, trauma, reconstructive foot and ankle surgery, diabetic limb preservation, and complex forefoot and rearfoot pathology. He is recognized for his ability to translate advanced surgical techniques into practical, real-world outcomes for patients of all ages. Beyond clinical practice, Dr. Glazer is deeply committed to education, as he is the Scientific Director of "The Western", a prominant Podiatric Medical Symposium! , mentorship, and the advancement of the podiatric profession. He regularly contributes to professional development through teaching, public education, and collaborative work with peers across multidisciplinary healthcare teams. On this channel, Dr. Glazer shares: • Expert insights on foot & ankle health • Fellowship surgical education • Innovations in podiatric medicine • CME in Podiatry Whether you are a patient, student, or healthcare professional, Dr. Glazer's content is designed to educate, empower, and elevate the standard of foot and ankle care. Enjoy!

Join CCL's VP of Field Operations for a training that will preview CCL's new “BRIDGE” program - Building Relationships in Dialogue, Growth, and Engagement. Brett will preview the framework that offer practical insights for having more effective, empathetic climate conversations that build understanding and momentum for change. A relational advocacy program based on behavioral and social science from Drs. Haidt, Willer, Cialdini; Amanda Ripley; and more. The program will serve as one of the foundational building blocks for Citizens' Climate's advocacy. Understand people's underlying moral foundations, and learn to practice moral reframing across political perspectives. The program will also teach participants to apply practical dialogue techniques to bridge divides and engage effectively with people holding different views.

It's the middle of December, which means we're in the midst of what we like to call Finals Season here in the US of A. It's a time when students around America are buckling down, going over flash cards, and trying their best to make up for having not paid attention in class for the last few months. Today Producer Jakob has asked Drs. Johnny Lupinacci and Tim Slekar to recount their own study habits, give some friendly studying advice to current students, and tell some hilarious stories from finals' past. Whether you shall choose to cram, or not to cram, you'll be more than prepared thanks to THIS studious episode of the Producer's Choice Show! The Producer's Choice Show with Producer Jakob is part of BustED Pencils: Fully Leaded Education Talk which is part of Civic Media. Subscribe to the podcast to be sure not to miss out on a single episode! Go to bustedpencils.com for swag, all of our episodes, and for information on partnering with us! For information on all of the programming across the Civic Media network, head over to https://civicmedia.us/shows. Join the conversation by calling or texting us at 608-557-8577 to leave a message! Guests: Dr. Tim Slekar, Dr. Johnny Lupinacci

In this episode of the AgNext Podcast, Kim and Pedro are joined by Drs. Eduardo de Paula and Sara Place to discuss the new in-vitro system the AgNext team is bringing online. Tune in to learn how this cutting-edge technology will advance our sustainable animal agriculture research.In this episode of the AgNext Podcast, Dr. Kim Stackhouse-Lawson joins Pedro as a guest discussing one of her publications that investigated if the U.S. cattle supply chain could achieve net zero. She walks through the study's design, key findings, and the critical need for continued research and innovation to advance sustainable animal agriculture.About AgNextAgNext is at the forefront of research in animal and ecosystem health, dedicated to enhancing the profitability of the supply chain. Serving as a crossroads for producers, industry partners, and researchers, AgNext drives innovation in sustainable animal agriculture. Our research focuses on advancing the science of animal agriculture to ensure a safe, secure, and nutritious food supply. Our mission is to identify and scale innovations that foster animal and ecosystem health, promoting profitable industries that support vibrant communities. Learn more at ⁠agnext.colostate.edu⁠⁠. Music Credit, Producer, and Artwork Song: Tony Petersen - Dusting the Broom (downloaded from Artlist) Producer: Erica Giesenhagen Artwork: Julia Giesenhagen

My conversation with Dr Caplan begins at about 29 minutes after the "shit show" Come to tonight's Hangout! Join us in Vegas for Podjam 3! Subscribe and Watch Interviews LIVE : On YOUTUBE.com/StandUpWithPete ON SubstackStandUpWithPete Stand Up is a daily podcast. I book,host,edit, post and promote new episodes with brilliant guests every day. This show is Ad free and fully supported by listeners like you! Venmo at the bottom! Please subscribe now for as little as 5$ and gain access to a community of over 750 awesome, curious, kind, funny, brilliant, generous soul Dr Arthur Caplan who is currently the Drs. William F and Virginia Connolly Mitty Professor and founding head of the Division of Medical Ethics at NYU School of Medicine in New York City. Prior to coming to NYU School of Medicine, Dr. Caplan was the Sidney D. Caplan Professor of Bioethics at the University of Pennsylvania Perelman School of Medicine in Philadelphia, where he created the Center for Bioethics and the Department of Medical Ethics. Caplan has also taught at the University of Minnesota, where he founded the Center for Biomedical Ethics, the University of Pittsburgh, and Columbia University.  He received his PhD from Columbia University Follow Dr Caplan on Twitter and let him know you heard him here! On YOUTUBE.com/StandUpWithPete ON SubstackStandUpWithPete Pete on Blue Sky Pete on Threads Pete on Tik Tok Pete on YouTube  Pete on Twitter Pete On Instagram Pete Personal FB page Stand Up with Pete FB page   Gift a Subscription https://www.patreon.com/PeteDominick/gift Send Pete $ Directly on Venmo  

Today's episode of STEM-Talk features a timely and wide-ranging discussion with Drs. Michael Griffin and Lisa Porter about NASA's plans to return humans to the Moon, the history of lunar missions, and how China's advances in space technology pose a serious threat to U.S. national security. IHMC founder and CEO Emeritus Ken Ford's interview with Griffin and Porter came 10 days before Griffin appeared before the U.S. House Committee on Science, Space and Technology to give testimony on China's advancements in space and the risks it poses for the United States. “We have squandered a 60-year head start on pioneering the space frontier to a nation that, without reason or provocation on our part, has chosen to become our nation's adversary,” said Griffin in his opening comments to Congress. In this episode, Griffin and Porter explain why it is critical for the U.S. to return to the Moon before China. They also argue that NASA's Artemis III mission to return to the lunar surface and establish a permanent base on the Moon is seriously flawed and should be scrapped. Griffin and Porter are co-founders and co-presidents of LogiQ Inc., a company providing high-end management, scientific and technical consulting services. Griffin's background includes roles as the former Undersecretary of Defense for Research and Engineering, the Administrator of NASA, the Space Department Head at the John Hopkins University Applied Physics Laboratory as well as Chairman and CEO of Schafer Corporation. Porter's background includes roles as the former Deputy Undersecretary of Defense for Research and Engineering, the founding Director of the Intelligence Advanced Research Projects Activity (IARPA) in the Office of the Director of National Intelligence, and the Associate Administrator for Aeronautics at NASA. Show notes: [00:04:44] Ken opens the interview by welcoming Mike back to STEM-Talk, who was a guest on Episodes 23 and 134. He also welcomes Lisa to her first appearance on STEM-Talk and asks her to talk about her decision to major in nuclear engineering at the Massachusetts Institute of Technology. [00:08:50] Ken asks Lisa why she went to Stanford for a Ph.D. in physics. [00:10:43] Ken explains that Lisa was the founding director of the Intelligence Advanced Research Projects Activity (IARPA), a department within the Office of the Director of National Intelligence. Ken asks about some of the challenges the American intelligence community faced that she addressed as director of IARPA. [00:16:15] Ken asks about Lisa's time working for Mike as Associate Administrator for Aeronautics at NASA, and how she came to accept that role. [00:18:07] Ken explains that when Mike became Undersecretary for Defense for Research and Engineering in 2018, he invited Lisa to become the Deputy Undersecretary for Defense for Research and Engineering. Ken asks Mike why Lisa was ideal for that role. [00:21:07] Ken explains that Mike and Lisa are working together again as co-founders and co-presidents of LogiQ Inc., a company that provides scientific consulting services. Ken asks Mike to give a brief overview of LogiQ's work. [00:24:44] Ken shifts the discussion to space exploration, noting that he wants to talk about Mike's 2024 congressional testimony on returning to the Moon, and a paper that he and Lisa published titled “A system architecture for human lunar return.” To begin the discussion, Ken asks why it is so important for us to return to the Moon. [00:29:11] Ken asks Mike and Lisa to explain why it is important for the US to be the first to return to the Moon in the context of China's ambition to send humans to the Moon and establish a permanent lunar presence. [00:33:24] Ken asks Mike and Lisa if they see the cancellation of the Apollo program as a mistake. [00:35:36] Ken asks Mike and Lisa to give an overview of the Artemis program. [00:41:45] Ken mentions the centrality of the Gateway in the Artemis plan, and the problem with making something that is already hard even harder for no good reason. [00:43:28] Ken mentions his concern that the focus on a Mars-forward approach might impede our success with the current Moon missions. [00:46:40] In Mike and Lisa's aforementioned paper, they propose a dual-launch lunar landing architecture, which is simpler than the current NASA architecture and presents lower risks to the crew. Ken asks Mike and Lisa to elaborate on this idea. [00:48:41] Ken asks Mike and Lisa what they think are some of the other technical and programmatic problems with the current Artemis plan. [00:52:31] Ken asks Mike and Lisa what NASA's response has been, as well as the response of others in the human space flight community, to their paper and recommendations for the Artemis mission architecture. [00:54:25] Ken explains that Sean Duffy, the Secretary of Transportation and acting NASA administrator, has opened the door to some additional lander ideas in light of concerns that the two current contractors, Space X and Blue Origin, may not be ready in time for the current Artemis schedule. Ken asks if Lisa and Mike think this is a good idea or if they think it would further complicate matters. [00:59:25] NASA's current budget is around $24.9 billion dollars, approximately 0.4 percent of total federal spending. Ken notes at a time when China is increasing their investment in their space programs and launching several missions, NASA is facing a proposal to cut its funding by 24 percent to $18.8 billion. Ken asks Mike and Lisa for their thoughts on this. [01:03:13] Ken and Lisa continue Mike's discussion on the core purpose of NASA beyond science. [01:08:55] Ken and Mike reflect on Ken's observation that the U.S. is not as serious about space and the Moon as it was during the Apollo years, years that attracted the nation's best and brightest. [01:09:39] Ken asks Mike and Lisa their thoughts on the way that NASA is contracting more services in the development of Artemis, rather than funding a development program. [01:15:55] Ken wraps up the interview by commenting that he believes listeners will very much enjoy today's conversation. Links: Michael Griffin bio Griffin's Dec. 4 2025 Congressional testimony Griffin's 2024 Congressional testimony Lida Porter bio Ken Ford bio Ken Ford Wikipedia page Learn more about IHMC STEM-Talk homepage  

Meg and Spanners are back for one last ride to talk about all the burning questions and scenarios that can be expected for the 2026 F1 season. They talk about the massive new regulations, what to hope for from Cadillac, and all the big team changes for 2026. (00:00) Intro (03:16) What to expect from new regulations (21:31) Title favorite predictions (31:51) Will we miss DRS? (36:02) What do we want out of Cadillac? (45:15) New rookie on the block (48:25) A new engine partnership (53:25) Team changes for 2026 Host: Megan Schuster Guest: Spanners Ready Senior Producer: Steve Ahlman Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this week's podcast, we sit down with Drs. Sarguni Singh, Christian Furman, and Lynn Flint, three authors of the recent Journal of the American Geriatrics Society article, "Rehab and Death: Improving End-of-Life Care for Medicare Skilled Nursing Facility Beneficiaries."  The authors dive into the challenges facing seriously ill older adults discharged to Skilled Nursing Facilities (SNFs), where fragmented care transitions, misaligned Medicare policies, and inadequate access to palliative care often result in burdensome hospitalizations and goal-discordant care.  The discussion highlights key barriers in Medicare's SNF and hospice benefits, including the inability to access concurrent hospice and SNF care, and explores solutions to improve care. Among the recommendations is leveraging Medicare's Patient Driven Payment Model (PDPM) to reimburse SNFs for providing palliative care, commissioning a Government Accountability Office (GAO) report on SNF utilization at the end of life, and piloting a model that allows time-limited concurrent hospice and rehabilitation care.  Also, check out these two resources if you want a deeper dive: Our past podcast we did, now nearly 6 years ago, on the original NEJM paper, Rehabbed to Death. Joan Carpenter's article titled "Forced to Choose: When Medicare Policy Disrupts End-of-Life Care" in the Journal of Aging & Social Policy  

Welcome to the Leading Edge in Emotionally Focused Therapy, hosted by Drs. James Hawkins, Ph.D., LPC, and Ryan Rana, Ph.D., LMFT, LPC—Renowned ICEEFT Therapists, Supervisors, and Trainers. We're thrilled to have you with us. We believe this podcast, a valuable resource, will empower you to push the boundaries in your work, helping individuals and couples connect more deeply with themselves and each other. Step into a heartfelt conversation where  Dr. James Hawkins and Nicola Hawkins explore the art of externalization in emotion-focused therapy. This episode delves into how therapists can gently guide clients into their most vulnerable spaces without overwhelming them—using creative, compassionate externalization techniques. Listeners will find practical strategies, authentic reflections, and moments of inspiration that underscore the importance of safety, attunement, and reintegration throughout the therapeutic journey. It's a compassionate guide for every EFT therapist looking to expand their “toolkit” for helping clients move courageously into their own healing. Top Points from the Episode: - Upcoming training opportunities in EFT and gratitude for the therapy community, especially during challenging times. - The concept of externalization as a gentle intervention to help clients face vulnerability when direct approaches would overwhelm. - Creative metaphors and analogies—for example, “letting clients breathe but not leave”—to describe how to stay connected and supportive in tough moments. - Techniques for externalization: using third-person references, prototypes, past versions of self, and broader narratives to create safety. - The crucial process of reintegrating externalized parts to support clients' healing and growth. - Reflection on the therapist's role in providing validation, understanding, and new perspectives. - Practical adaptations for different cultural and client contexts, ensuring inclusivity and relevance. - Emphasis on co-creating meaning—from reframing past experiences to fostering autonomy and choice within sessions. - Encouragement for therapists to remain flexible, observant, and compassionate when clients hit emotional blocks. - Inspiring reminders about the transformative power of working on the client's “leading edge”—where real change happens. We aim to equip therapists with practical tools and encouragement for addressing relational distress. We're also excited to be part of the team behind Success in Vulnerability (SV)—your premier online education platform. SV offers innovative instruction to enhance your therapeutic effectiveness through exclusive modules and in-depth clinical examples.  Stay connected with us: Facebook: Follow our page @pushtheleadingedge Ryan: Follow @ryanranaprofessionaltraining on Facebook and visit his website James: Follow @dochawklpc on Facebook and Instagram, or visit his website at dochawklpc.com George Faller: Visit georgefaller.com If you like the concepts discussed on this podcast you can explore our online training program, Success in Vulnerability (SV). Thank you for being part of our community. Let's push the leading edge together!

Welcome to the Leading Edge in Emotionally Focused Therapy, hosted by Drs. James Hawkins, Ph.D., LPC, and Ryan Rana, Ph.D., LMFT, LPC—Renowned ICEEFT Therapists, Supervisors, and Trainers. We're thrilled to have you with us. We believe this podcast, a valuable resource, will empower you to push the boundaries in your work, helping individuals and couples connect more deeply with themselves and each other.   In this episode, James and Nicola dive deep into the concept of transparency in therapy and training. They explore how openness about intentions, the process, and emotional reactions creates safety, builds trust, and models vulnerability for both clients and therapists. The discussion includes practical examples, personal stories, and tools for effective therapeutic transparency, plus a rundown of upcoming training events. To support our mission and help us continue producing impactful content, your financial contributions via Venmo (@leftpodcast) are greatly appreciated. They play a significant role in keeping this valuable resource available and are a testament to your commitment to our cause. We aim to equip therapists with practical tools and encouragement for addressing relational distress. We're also excited to be part of the team behind Success in Vulnerability (SV)—your premier online education platform. SV offers innovative instruction to enhance your therapeutic effectiveness through exclusive modules and in-depth clinical examples.  Stay connected with us: Facebook: Follow our page @pushtheleadingedge Ryan: Follow @ryanranaprofessionaltraining on Facebook and visit his website James: Follow @dochawklpc on Facebook and Instagram, or visit his website at dochawklpc.com George Faller: Visit georgefaller.com If you like the concepts discussed on this podcast you can explore our online training program, Success in Vulnerability (SV). Thank you for being part of our community. Let's push the leading edge together!

In part one of this two-part series, Dr. Dan Ackerman talks with Drs. Valérie Biousse and Nancy J. Newman about the clinical presentations, diagnostic challenges, and the importance of accurate diagnosis in managing CRAO and BRAO.  Read the article referenced in this interview in the Journal of Stroke & Cerebrovascular Diseases.  Disclosures can be found at Neurology.org.  

01. Seventhrun - Ashes To Light 02. Feed the Fire - Let Go 03. Dapreme, ADUKEN, Licia - Bleed For You 04. Wilkinson, iiola - Back Up 05. T & Sugah - Pam Pam 06. Tantrum Desire - Killerz 07. Used, Lily Denning - Control 08. Solomon France - Down Bad 09. Document One - Spin Doctor 10. TURNO, Clarkey, Kay Rico Light Up The Rave 11. Kanine, Arcando, HEIGHTS - Lost Tonight 12. Axel Boy, Afroditetoolively - Nowhere to Hide (blkout. Remix) 13. Misanthrop - Deep Down Raw 14. Midnight CVLT, Ric Waves - Echo Protocol 15. oneBYone & Oneder - Boom Bang 16. Double Medley, Subminderz - Get It Straight 17. Minimalist - Tribe 18. Prolix - Space & Time 19. Gancher_&_Ruin - Моя_Печаль_Vocal_Mix 20. MIDNIGHT CVLT x PROLIX - Shadows In The Dark 21. Magnetude feat. The Velvet Effect - Silhouette 22. MNDSCP - Raw 23. MIDNIGHT CVLT - Back Home 24. Pythius - All You Need 25. Exit4 - Red vip 26. Inerpois, Backup - Brain Error 27. Absu_NTQL - Lifeform 28. Frosta - No Mercy 29. Kvostax&Unquiet&Exit4 - F**ing Daiting 30. [BORDERS], Puzzle - Against All Odds 31. Break - All You Gotta Do 32. Dunk - Dark Clouds 33. OODINI - Jazz Anthem 34. Trail, Objectiv - Pitch Dark (Objectiv Remix) 35. Keeno - Follow 36. Irah, Goddard. - Eye Of The Storm 37. Basstripper - Ready For It 38. JFlux - All Points Squared 39. 2Whales - Ryadom 40. INDIKINO, Sovsem dikaya - More Dyshit 41. Ozma, Женя Винд - Орёл 42. Fakear - waking up is better with you (Remix, extended) 43. DJ Science - One Love, Dubwise 44. AnnGree - What I Had To Do 45. Loud.Drop - Metal Chicken 46. Octavate - The Walls 47. Molecular, En:vy - Speed Racer 48. Furniss - End of time 49. GGrossy - Alarming Surge 50. Maurizzle, Justin Hoffmann Pistolero 51. Pruf - Ice 52. Magenta & GR4HM - Lock It Off 53. DOWNCAST - Bad Boy (Extended Mix) 54. Subrix - Dubplate 88 55. FooR, CLSM - Hardcore Vibes 56. Dem MC - The Roots of Existence 57. Mr Quest - Break The Script 58. Discord - Two Sides To This Story 59. Doom Poets, Technical Itch - THROUGH THE SEAS 60. Grey Man - Believe 61. Glitch City & DJSS ft Blaxx & Maddy V - WHY Contagion Remix 62. Uneven - The Unknown 63. Ahmad - Burn 64. Fetus - Half Half (Amor Satyr Remix) 65. Spirit - International (London Mix) 66. Heavyweight - Holy Grail 67. Hyperfocus - If You Know 68. Sonic Art x Kayaman - Untitled_Jam (Dissident Remix) 69. FRACTURE, NEPTUNE - Erase Everything 70. Primal Tribes - Whispering Silence Crawls On Me 71. GIROSKOP - Darkway 72. DRS, Zar - Handle Us 73. Kleu, Leanne Louise - Complicated 74. Majestic, Jungle 70 - Creeping In The Dark (Danny Byrd Extended Remix) 75. 30Hz - Dark Matter 76. Royalston feat. Jaynee - Sour 77. Telomic & Sam M - Holding On 78. Spectrum - Altered Perception 79. Calibre - Don't Feel For Me 80. Jonathan Baker Silver 81. Promenade - Always You 82. Lsb - PCT

Drs. Priya Vakharia and Sarwar Zahid join host Dr. Jay Sridhar to discuss the history, major recent changes, and future of the Good Days Chronic Disease Fund as it pertains to medical management of patients with retinal disease. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Send us a textIn this powerful solo episode, Andrea Atherton invites listeners into the heart of conscious love through the transformative framework of 8 Dates by Drs. John and Julie Gottman. With her signature blend of warmth, depth, and clinical wisdom, Andrea unpacks the research behind the book and reveals why these eight core conversations are essential for creating a relationship anchored in trust, intimacy, and emotional truth. This episode is an invitation to step into intentional love—whether you're dating someone new or committed to strengthening a long-term partnership.Andrea gently guides listeners through each of the eight topics, illuminating how they shape the inner architecture of a healthy relationship. She explores the emotional significance behind trust, conflict repair, intimacy, money, family history, play, personal growth, and long-term vision. Listeners will learn how to communicate their needs with clarity, how to listen with generosity, and how to build relationship rituals that deepen connection over time. Andrea's guidance offers both practical tools and heartfelt inspiration, making these conversations feel accessible, empowering, and deeply human.This episode is perfect for anyone longing for love that feels safe, courageous, and alive. Andrea offers reflection prompts, communication practices, and gentle suggestions to help you bring these conversations into your own relationship with intention and grace. Episode 231 is more than an exploration of the 8 Dates framework; it is a reminder that meaningful love is created moment by moment, conversation by conversation, when we dare to show up with honesty and an open heart.30-minute Consultation with Andrea https://www.andreaatherton.com/booking-calendarAndrea Atherton Websitehttps://www.andreaatherton.com/Love Anarchy Websitehttps://www.andreaatherton.com/podcasthttps://loveanarchypodcast.buzzsprout.comLove Anarchy Facebookhttps://www.facebook.com/loveanarchypodcast/Andrea Atherton Facebookhttps://www.facebook.com/andreaatherton-17/

Dr. Alison Loren and Dr. Ann Partridge share the latest guideline from ASCO on the management of cancer during pregnancy. They highlight the importance of this multidisciplinary, evidence-based guideline and overarching principles for the management of cancer during pregnancy. Drs. Loren and Partridge discuss key recommendations from each section of the guideline, including diagnostic evaluation, oncologic management, obstetrical management, and psychological and social support. They also touch on the importance of this guideline and accompanying tools for clinicians and how this serves as a framework for pregnant patients with cancer. The conversation wraps up with a discussion on the unanswered questions and how future evidence will inform guideline updates.  Read the full guideline, "Management of Cancer During Pregnancy: ASCO Guideline" at www.asco.org/survivorship-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/survivorship-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-02115   Brittany Harvey: Hello and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Alison Loren from the Perelman School of Medicine of the University of Pennsylvania and Dr. Ann Partridge from Dana-Farber Cancer Institute, co-chairs on "Management of Cancer During Pregnancy: ASCO Guideline." Thank you for being here today, Dr. Loren and Dr. Partridge. Dr. Alison Loren: Thanks for having us. Dr. Ann Partridge: It's a pleasure. Brittany Harvey: And then just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Partridge and Dr. Loren who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into the meat of this guideline, to start us off, Dr. Loren, could you provide an overview of the scope and purpose of this new guideline on the optimal management of cancer during pregnancy? Dr. Alison Loren: Sure, thanks, Brittany. So this was really born out of I think a lot of passion and concern for this really vulnerable patient population. We have observed, and I am sure it is not any surprise to your audience, that the incidence of cancer in young people is increasing. And simultaneously, people are choosing to become pregnant at older ages, and so we are seeing more and more people with a cancer diagnosis during their pregnancy. And for probably obvious reasons, there is really no way to do randomized clinical trials in this population. And so really trying to assemble and articulate the best evidence for safely managing the diagnosis of cancer, the management of cancer once it is confirmed, being thoughtful about obviously the health of the mom, but also attending to potential risks to the developing fetus, and really just trying to be really comprehensive and balanced about all the choices for these patients when they are facing some really challenging decisions in a very emotionally fraught environment. And I think it is really emotionally fraught for the providers, too. You know, this is obviously an extremely intense, very emotional set of decisions, and so trying to provide a rudder essentially to sort of help people frame the questions and trying to make as evidence-based a set of recommendations as possible. Dr. Ann Partridge: And I would just add that "evidence-based" is a strong word here because typically our, as you just heard, our gold standard evidence is a randomized trial, but you can't do that in this setting, in general. And so, what we were able to do with the support of the phenomenal ASCO staff was to pull together kind of the world's literature on the safety and outcomes of treatments during pregnancy, as well as consensus opinion. And I think that is a really, really critical difference about this particular guideline compared to many of the other ones that ASCO does, where consensus and good judgment needed to kind of rule the day when evidence is not available. So, there is a lot of that in our recommendations. Dr. Alison Loren: That is such a good point. And I just, before we move forward, I just want to reflect that the composition of the panel was really broad and wide-ranging. We had maternal medicine specialists, we had legal and ethical experts, we had representatives who understand pharmaceutical industries' perspectives, and then medical oncologists representing the full spectrum of oncology diagnoses. And so it was a really diverse, in terms of expertise, panel, internationally composed to try to really get the best consensus that we could in the absence of gold standard evidence. Brittany Harvey: Absolutely. That multidisciplinary panel is really key to developing this guideline and, as you said, looking at the evidence and even though it does not reach the level of randomized trials, still critically evaluating it and reviewing that along with consensus to come up with optimal management for diagnosis and management of cancer during pregnancy. So then to follow that up, I would like to next review the key recommendations of the guideline across the main sections that the expert panel provided. First, I will throw this out to either of you, but what are the important general principles for the management of cancer during pregnancy? Dr. Ann Partridge: I think there were three major principles that we hammer home in the guidelines. One is that this is a team sport. It is multidisciplinary care that is necessary in order to optimize outcomes for the patient and potentially for the fetus. And that you really need to, from the beginning, bring in a coordinated team, including not just oncologists but obstetricians, maternal-fetal medicine specialists, neonatologists, ethics consultants, and obviously the patient and potentially her family. So that, I think, is one of the most important things. Second would be that obviously in a pregnancy, there are two potential patients and that the nuances of safety and risk from treatment is really wrapped up in where in the trimester of the pregnancy the patient is diagnosed, along with the kind of cancer that it is, both the urgency of treatment and the risk of the cancer, as well as the potential risks of any given intervention across the cancer continuum. It is a broad guideline in that regard. And then finally, and this is particularly timely given what is going on from a sociopolitical standpoint in the U.S., really thinking about informed consent and potential ethical as well as legal implications of some of the choices that patients might have when they are thinking about, in particular, continuing a pregnancy or potential termination. Dr. Alison Loren: And I will just add that I think that the key to all of this guidance is nuance and individualization and also making sure that patients and their care providers understand all the choices that are available to them and also the consequences of those choices. You know, nobody would choose to receive chemotherapy during pregnancy if that wasn't necessary. So there are risks to treatment, but there are also risks to not treatment. And making sure that in a suboptimal situation where you do not have a lot of evidence, trying to weigh, the best you can, the risks and benefits of all of the choices so that the patient can come to a decision about the treatment plan that is right for her. Brittany Harvey: Definitely. And those core concepts really set the stage for individualized care on what is necessary for appropriate multidisciplinary care, prioritizing both patient autonomy and informed decision making. With those core concepts and key principles in mind, I would like to move into the recommendations section of the guideline. So what are the key recommendations regarding diagnostic evaluation for pregnant patients with signs or symptoms of cancer? Dr. Alison Loren: I think the most important thing is to not delay, that there are very careful and well-thought-out recommendations for how to evaluate a potential cancer. And while there are certain things that we know can be harmful, particularly when certain dose thresholds are exceeded - for instance, abdominal imaging, there are certain radiographic thresholds that you don't want to exceed because of risk of harm to the embryo or fetus - there are still lots of options for diagnosing cancer during pregnancy. And again, thinking about the costs of not doing versus the cost of doing, right? It is really important to make the diagnosis of cancer if that is a consideration or a concern. And sometimes going directly to biopsies or getting definitive studies, even if there is a small risk to the developing fetus, is really essential because if the mom does not survive, of course, the fetus is also not going to survive. And so we need to be thinking first about the patient who is sitting in front of us, the woman who needs to know what is going on in her body so she can make good decisions about her health. So, I think that is a key principle in thinking about this. Brittany Harvey: Absolutely. So, following that diagnosis of a new or recurrent cancer, what is recommended for oncologic management of patients who are diagnosed with cancer during their pregnancy? Dr. Ann Partridge: So, I think the general principle is, again, cancer is such a wide number of diseases and even within diseases, a range of stages and risks and associated opportunities for risk reduction and/or treatment depending on the type of cancer. Just by example, in the work that I do, which is breast cancer, once someone has had a surgery in the early-stage setting, a lot of our treatment is about risk reduction. And that is very different than from what Alison does, which is treating people with leukemia, where it is kind of binary. If you do not treat, including with cytotoxic drugs, the patient and an unborn fetus will die, especially early in the pregnancy, obviously. So this is where cancers are very, very different. So I think taking the approach of what would you do if the patient were not pregnant? And what is the best treatment for that particular patient with that particular kind of cancer? And then applying the pregnancy and where the patient is in that pregnancy in terms of the trimester of the pregnancy, and what is safe and what is unsafe from the options that you would give her if she were not pregnant. And then if the patient is choosing to keep the pregnancy, which in my practice, many people come and they come to me because they want to hold onto their pregnancy and want to figure out how to make it work, coming up with a regimen that tries to give them kind of the best bang for the buck, the best possible breast cancer therapy with the least harm, when possible, to the fetus. It is a bit of a balance, right? And then we cannot always give people the best approach. And sometimes it comes down to making a decision to give up something that may improve their survival so as not to harm the fetus. And sometimes it goes the opposite direction where a patient will say, "Oh, that is going to improve my survival by 5% and you can't give it to me now? I am going to choose to terminate." Even though that is obviously a very, very difficult and challenging decision to make in this setting because they want to optimize their survival and ideally live on to potentially have another pregnancy in the future if that is something that is of interest to her. So these are really, really hard conversations as you can imagine, but that is kind of where we go. Dr. Alison Loren: Yeah, and I think this is where the need for more research and understanding is really key because sometimes questions come up. I guess I am thinking about like HER2-directed agents, which we know are contraindicated in pregnancy. But what about sequencing? Does it matter when you get it? Can you get it later? I think that is something that we don't really fully understand. And similarly, again, this is obviously like a breast cancer and blood cancer focused discussion because that is what we do, but thinking about managing blood cancers, certainly with acute lymphoblastic leukemia, there is actually a lot of options now that, you know, you could potentially use to temporize or sort of get somebody through a pregnancy relatively safely. I am focusing on the word "relatively" because we do not know what the long-term impact might be of potentially not optimal therapy in the long run. And then thinking about other things like timing of a bone marrow transplant relative to either delivery or termination. I mean, again, we really do not know what are the right sets of sort of timing considerations for those. So there are just a lot of unknowns. And I think trying to be sort of self-aware and humble and honest about those unknowns so that the patient can engage in the conversation in a way that is meaningful to her and make the decisions that make the most sense for her. I think the most important thing is to make sure that the patient feels supported and safe to make those decisions with as little regret as possible. Brittany Harvey: Yes, I think it is really important that you mentioned that there is a wide range of cancers here, and that means that care really needs to be individualized for each patient. I will also note, just in this section, that I found really informative while reading through the guideline the list of oncologic agents that may be offered in each individual trimester, whether it is contraindicated or it can be used with caution, or if there is relatively good safety data on it for prioritizing maternal treatment needs and balancing fetal safety at the same time. I think that is, that is really key. And I think readers will really like that section of the guideline to provide concrete information for them and their patients. Dr. Alison Loren: Thank you. We actually spent a lot of time on that table and just thinking about what it should look like, what the format ought to be, what the language ought to be. Because of course, at the end of the day, everything should be used with caution. So what does that actually mean? And we sort of tried to explicate that a little bit in like the footnotes. We really tried to leverage what we know from clinical experience, from package labels, from mechanism of action to try to be as clear and definitive as we could be without overstating or understating what we know. Dr. Ann Partridge: Yeah, and I think we are focusing on breast and leukemia because that is what we do. But the truth is much of the data comes from those two areas. Leukemia, not because it is so common, but because you do not really have choices to treat or not treat. And so for decades, they have been treating and saying, "We hope the progeny comes out okay." And for many agents it does. The babies are okay. And so, we have reasonable observational data. And then in breast cancer, there have been actually some prospective registry-type studies where people have been followed and treated when pregnant, and the progeny have been accounted for, and so we have some good experience in that way too. Again, not randomized trials, but at least data that suggests certain agents are safe. And increasingly, because of that, when we have had to treat patients, we have said, "Okay, let us do it on this registry so that we can at least learn from every patient that comes in in this situation." And so, I think we will have more and more data given the growing number of young adults with cancer and the delays in childbearing that are happening around the world, and particularly in Westernized countries. I wish we did not. We wish we did not see this problem, but of course, when we do, we have to make sure that we learn from it and try and get patients enrolled in these registries and any kinds of studies that are available. Dr. Alison Loren: Yeah, I will just underscore that to say that, you know, there is outcomes of pregnancy and then there is outcomes of pregnancy, right? So there is like, "Okay, the baby was born with 10 fingers and 10 toes, and they passed their Apgar, and they are doing all their developmental processes along the way." But what happens when they are 10 or 15 or 20? Are they maturing normally? Are they cognitively intact? And then, of course, it is really inseparable from what is the impact on a family of having the mom with cancer? And how does that impact childhood development and intellectual development? And so these are really, really important questions that are very difficult to answer given the longitudinal information that you need, but it is a really critical question that, you know, patients ask and we do not know the answer. Dr. Ann Partridge: Yeah, that actually leads me to one of the important principles in the guideline that is a little bit of a change from when I first started practicing, which is we have learned from the wider neonatology literature, as they have followed up on the children that were born prematurely, that it is actually better not to be premature and to keep the baby in utero as long as it is safe for the fetus and the mother as long as possible, ideally to term rather than delivering early and then giving the chemo after that or separating the chemo from before and after. We used to try and deliver early and then give agents, but now we typically will give agents that are safe to be given at the end of pregnancy, ideally close to term, a couple weeks out, to allow for the ability of count recovery, and you do not want to go into preterm labor with chemotherapy on board, but we used to go much earlier and have an argument with our maternal-fetal medicine doctors. "How early can you get them out?" And they would say, "How long can they stay in?" And increasingly, we have been able to try and compromise to go even later and allow the fetus to go to term because of the neonatal outcomes that in longer term there is a suggestion that the children are developing better in the long run if they are kept in utero for as long as possible. Dr. Alison Loren: Yeah, that is such a great point. I think that is probably the most important thing for people to take away. For anyone who sort of does this, I mean, no one does this regularly because it is a rare event, although I think it is increasing as I mentioned. But this idea that the third trimester is, most of us know, is primarily a time for growth. Most of the critical development has already occurred, and so administering most chemotherapy agents towards the end of the third trimester seems to be preferable long term than delivering them early. So that is a really big change. I think we used to try to sort of, "Oh, get them to 30 or 32 weeks and then deliver," but we really are trying to get them closer to term, 37 weeks or more, and then coordinating the treatment so that they are not nadiring, as Ann said, at the time of planned delivery. Brittany Harvey: Yes, and that is a really important point related to evidence-based care and why we have changed that practice. And so then that actually leads nicely into my next question. But as you both mentioned, this is an important collaboration between oncologists and obstetricians. So the next section of the guideline addresses obstetrical practice. And so beyond what is standard, what additional recommendations are there in obstetrical management for pregnant patients with cancer? Dr. Alison Loren: That is a great question. So I will say we were really struggling with like how much do we cover? Like this is an oncology guideline. We are not obstetricians. We certainly had great representation from our maternal-fetal medicine colleagues on the panel. But really trying to sort of give useful information without overstepping. And so I think that the main recommendations are to increase the frequency of fetal monitoring, make sure that there is close attention to blood counts in the patient. But I think there is really still a gap in terms of what we know about optimal management of a pregnant person who is receiving therapy and how to handle the pregnancy itself. The delivery should be a usual delivery. Our colleagues did not recommend a planned C-section. They recommended usual care in terms of planning for the delivery. Obviously, if a C-section is indicated, then it should be done, but it should not be planned this way because of the cancer diagnosis. And I guess the other thing that we mentioned in the guideline, although we were reluctant to push it too hard because of access to these specialized services, was evaluating the placenta after birth to ensure that there were no metastases in the placenta itself. Dr. Ann Partridge: Those are the main things, and judicious and prudent obstetrical care, as I think, you know, is trying to be practiced regularly with MFM. Typically these patients should be followed not by your average OB/GYN, but a maternal-fetal medicine specialist because these patients will have special concerns, especially if they are sick. So oftentimes, especially Alison's patients, are actually sick with leukemia. And so you are monitoring them a lot, whereas, you know, a breast cancer patient typically isn't sick, although they could get sick with their chemotherapy. And so we really want to hand-in-hand manage these patients with our MFM colleagues. Dr. Alison Loren: I think we also highlighted in the guideline just for the refresher purposes of the oncology community, generally which drugs that would be given in a normal oncology setting are safe to be given to a pregnant person. So we talked a little bit about what kinds of steroids are recommended, antiemetics, DVT prophylaxis, peripartum. These are things that we think about a lot in oncology, but just want to make sure that it sort of intersected appropriately with the care of a pregnant patient. Brittany Harvey: Definitely. That specialized care is really important for patients who are pregnant and have cancer. And then the last section of the recommendations addresses psychological and social support. As you both mentioned before, this is a highly emotional time and it can be difficult and challenging to make decisions. So what is recommended for the psychological and social support of pregnant patients with cancer? Dr. Ann Partridge: Well, as I said, it is really something that needs to be considered at the beginning, through the diagnostic period, all the way into survivorship. Ironically, even though it is a highly fraught, emotional situation, I find that my pregnant patients actually are extraordinarily resilient, and what they are really focused on often is the safety of the fetus, because again, many of the people that come to me, it is a highly wanted pregnancy. They are also focused on their own health, of course, and often you need to bring in social work, sometimes a psychologist, professionals who are there just to help manage their emotions while we are focusing on what do they need medically to be as healthy as possible, both for the again, the mother, the patient, and the fetus. It is very tricky, and I will say also bringing in sometimes people on the ethics team in the hospital to help, both from the "Are you recommending and giving something that is safe?" That is number one. And then number two, sometimes patients want to be treated with drugs that we do not have any safety data for in pregnancy. What are our obligations? I think most of us would say we would not treat someone if we do not have safety data and there is suspicion for concern. But where is that line in terms of the right thing to do by that patient? And so we are all beholden to our ethics colleagues to help us when we make decisions like that. You know, we all want to do right by the patient, but we have to uphold our oaths and legal obligations. I don't know if you have to add on that because it's very tricky. Dr. Alison Loren: It is, it is very hard. I mean, I think, you know, there is a lot of emotion, obviously any cancer diagnosis is extremely charged and people are already at sort of a heightened, you know, they are anticipating a new baby and planning around that. And so it is just an extremely disruptive is the smallest word I can think of to describe it. And I think that often there is a co-parent, there might be parents and in-laws and other siblings, and then there is care after delivery. And so it is just a very complex set of dynamics. And having both our ethics colleagues and our psychology and social work colleagues to sort of just pitch in and make sure that the patient is being supported. I think there are sometimes really difficult situations where maybe what the patient wants is different from what the father of the baby wants or what the rest of the family wants. And so that can be really challenging. And you never really know where those landmines are going to pop up. So it is good to have the team on board early and often. Dr. Ann Partridge: Yeah, I would add to that, the other thing here that I think is really important, like in all of medicine but especially in situations like this, this is where we have to be very careful as professionals not to impose our own ethical, moral, emotional, personal views on the patient and to try to reserve judgment as much as possible. We are their navigator with the most important evidence and information that we can provide in the current situation. And that is where this guideline is extraordinarily helpful, we hope, for clinicians in the years to come. And at the same time, we cannot necessarily impose our own views and what we would do on a patient or what we tell our daughters, sisters, friends, family members. It is very tricky in that way. And so sometimes not just support for the patient, but support for the care team may be warranted in some of these very fraught situations. Dr. Alison Loren: Yeah, that is such a great point. And I was sort of thinking that too. I mean, it is, of course, the patient is front and center, but these are really difficult situations to navigate. And I will just add also that a lot of times these patients end up in academic centers, which I think is that's where the expertise or even just the experience may be. But the downside of that is that, you know, the teams are constantly changing. You have a new resident, you have a new intern, you have a new attending, a new fellow. And so, you know, the patients may be subjected to lots of different ways of communicating and sometimes those perceived differences can be really challenging. So sort of team huddles to sort of make sure that everybody is reading from the same script and everyone is comfortable with how the information is being presented so that the patient does not feel more confused or more overwhelmed, that they are kind of getting a consistent message from the whole team that, "This is what we know, this is what we are recommending, here are your other choices, and here are the pros and cons of each of these options." Brittany Harvey: Yes, I think you have both touched on this and that bringing in appropriate experts to support both clinicians and patients and their decision-making and their mental health is really important for this section of the guideline. We have already discussed this a fair bit throughout our conversation, but in your view, what is the importance of this guideline and how will it impact both clinicians and pregnant patients diagnosed with cancer? Dr. Ann Partridge: I could start with that. We just talked about experts and having them all around, but the fact is most people do not have the experts all around when they are dealing with this. And I think this is, you know, an expert-based, evidence-based guideline where having this in one's back pocket, whether you are in rural Montana or at a major cancer center on either coast, you will be armed with the latest and the greatest in terms of what we know and what we do not know, and some very helpful algorithms for how to think through the process of dealing with a patient who is diagnosed during pregnancy, whichever type of cancer it is. We could not cover every single specific thing about every cancer, although it is a pretty long guideline and there is a lot of nuance in there. So you might find a lot about specific cancers. And I think that that will be very, very helpful for people who are faced with this situation in the clinics just to frame it out, think through. Sometimes there is no answer that is the perfect answer and then, you know, using this as kind of a scaffolding and phoning a friend who may have more experience to help guide you and guide the patient, most importantly. I think it will be very helpful in that regard. Dr. Alison Loren: Yeah, I think so too. And I have talked about that we are working on this guideline and the anecdotal feedback has been, "This is so helpful." Like there really has not been, I think, an all-in-one place, diagnostic considerations, radiographic considerations, staging, treatment, all the modalities, surgical, radiation, systemic chemotherapy. We tried to include, when we could, novel agents including targeted agents and monoclonal antibodies and bispecifics and cellular immunotherapies and non-cellular immunotherapies. We really, really tried to cover in 2025 what are people using to treat cancer and to try to give the most balanced view of what we think is is safe or reasonably safe and what we think is either unproven or known to be risky, really to have it be kind of a go-to, like all-in-one, as much information as we have about these really challenging cases. We tried to include, Ann mentioned, you know, specific cancers, and I think when there were specific things to shout out with specific cancers, we really tried to highlight that. Like, "Okay, lots of young patients with cancer have Hodgkin's lymphoma, so what is safe and what is not for that specific case?" Or, "What is safe or what is not when you are thinking about colon cancers?" And we have a shout-out in here about considering checking for DPD deficiencies in patients who are pregnant. And I know it is generally recommended nowadays, but certainly for people who are pregnant, you know, you really want to avoid excess toxicity. So I think just really trying to be attentive to specifics about certain cancers in young patients and what would be valuable for a practicing oncologist and obstetrician to know when you are faced with this situation. Dr. Ann Partridge: Yeah, and I think the other critical thing that is great about this guideline is it's a starting place. And I anticipate that we will be building on this guideline for many years to come. And remember that when first, I was not around then, but probably three or four decades ago, when chemotherapy was just coming out and patients were coming in pregnant, there was a feeling I am sure that was, "We cannot give this to this person because it is purposefully going to destroy cells. And when you destroy cells in a growing fetus, you are going to destroy or harm that fetus." And yet, people did not have great choices. It was get treated or die, especially with things like leukemia early on. And bold patients along with their oncologist said, "Bring it on." And that is how some of this literature has been born. And so moving forward, there will be either purposeful exposures or inadvertent exposures of some of our therapies where we will learn ultimately. And this is a place where we can update these guidelines. That is the beautiful thing about the ASCO guidelines is that they are constantly being thought about to be updated. And then when there is enough of a change in practice, they will be updated such that they will continue to inform how we do this in the years to come for patients who come in pregnant. Dr. Allison Loren: Yeah, and I will say I have been doing this long enough now, we were just talking about a different guideline, the fertility guideline earlier today, and over the 20 years that the fertility guidelines have been out, just the amount of research has really skyrocketed. And you can see as you look at each guideline how much we have learned, what we can say, "Yes, this is working," "No, this is not working." Like, it is stuff that we used to say, "Oh, we do not really know," and now we have answers.  I think I speak for both of us when I say that we are hopeful that this will serve as, as Ann said, as a starting off point and really inspire people to ask the questions and do the research so that we can give better guidance moving forward, really trying to think about, you know, mechanisms and leaning on our colleagues in pharma and in the government who sort of think about safety and efficacy, to sort of make sure that they are contemplating not just non-pregnant patients, but also pregnant patients or as they are thinking about marking the package inserts with safety guidelines around this. Brittany Harvey: Yes, this is a critically important first guideline on the management of cancer during pregnancy, and we will look forward to continuing to build on that. I think as you mentioned, this guideline is far-reaching and has a lot of recommendations in it. And so both the full text of the guideline and those at-a-glance algorithms, figures, and tables will be really useful for clinicians in their clinic. Finally, to wrap us up, we have just been discussing this a little bit, but specifically, what are the outstanding questions on the management of pregnant patients with cancer, and where is this further research needed? Dr. Alison Loren: There are lots and lots and lots of unanswered questions. And I think if you look at the table, most of what we say is, "We are pretty sure this is okay, we are not so sure about this." I am paraphrasing, but we really just are operating in a paucity of what we would normally consider gold-standard evidence. It is hard to imagine, of course, there would ever be, as we mentioned in the beginning, randomized trials. But I think that preclinical data, mechanistic data, trying to think about including as we go through animal data, making sure that we are looking at female animals and pregnant animals so that we can sort of fully understand what the impact may be. And then I think thinking about more localized therapies around sort of radiation, you know, we are now moving into really hyper-focused radiation treatments like protons. Is that better because there is less scatter? Like I think those are real considerations that we just do not know the answer to. What do you think? Dr. Ann Partridge: I think so many unanswered questions, and this is a call to action to continue to and increase the documentation of the experiences and outcomes for patients diagnosed during pregnancy. Dr. Alison Loren: Yeah, and I think the long-term outcomes too are really going to be critical. Brittany Harvey: Yes, we will look forward to learning about more evidence across the spectrum of care to inform future updates to this guideline. So I want to thank you both so much for your work to develop this guideline, to review the extensive amounts of literature that you did, and work to create this guideline. And thank you also for your time today, Dr. Loren and Dr. Partridge. Dr. Alison Loren: Thanks. It was fun. Dr. Ann Partridge: Yeah, thank you. Brittany Harvey: And finally, thank you to all of our listeners for tuning into the ASCO Guidelines Podcast. To read the full guideline, go to www.asco.org/survivorship-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. 

This bonus episode of DermSurgery Digest features interviews recorded live at the 2025 ASDS Annual Meeting to provide the top pearls, insights and takeaways from the premier dermatologic surgery meeting of the year, held in Chicago, IL, on Nov. 13-16, 2025. The practice management, surgical oncology and reconstruction sessions discussed, and the contributors featured are: Knots and Bots: Dermatologic Surgery in the Era of AI featuring Drs. Daniel Schlessinger and Kyle LauckBeyond the Textbook: Controversies in Cutaneous Oncology and Dermatologic Surgery featuring Drs. Jordan Lim, David Carr and Kathryn ShahwanUnlocking the Job Search: Tips for Residents and Early Career Physicians featuring Drs. Mona Sadeghpour and Yssra SolimanSkin Substitute Alternatives for Recalcitrant Postoperative Wounds featuring Drs. Tara Jennings and Ally-Khan SomaniAdvanced Reconstruction featuring Drs. Tara Jennings and Naomi Lawrence This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery.Cosmetic dermatologic surgery sessions are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net.

This bonus episode of DermSurgery Digest features interviews recorded live at the 2025 ASDS Annual Meeting to provide the top pearls, insights and takeaways from the premier dermatologic surgery meeting of the year, held in Chicago, IL, on Nov. 13-16, 2025. The cosmetic dermatologic surgery sessions discussed, and the contributors featured are: Integrating Cosmetic Surgery into Your Practice featuring Drs. Shawn Allen and Kyle LauckFat Grafting: New Discoveries and New Techniques featuring Drs. Lisa Donofrio and Megan McCleanASDS Glam Slam featuring Drs. Jamie Hu and Kyle LauckGLP-1: From Prescribing to Managing Volume Loss featuring Drs. Kavita Mariwalla and Sydney ProfferLower Face Cosmesis featuring Drs. Jean Carruthers and Ardalan MinokadehMaking the Most of Your Laser Settings featuring Drs. Paul Friedman and Pooja RambhiaNeuromodulators – The Cutting Edge featuring Drs. Deirdre Hooper, Rachel Pritzker and Sydney ProfferASDS Cosmetics Oral Abstract featuring Drs. Kyle Lauck, Aman Nihal and Nathalia Simonetti This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery.Practice management, surgical oncology and reconstruction sessions are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net.

In the November 2025 episode of Critical Decisions in Emergency Medicine, Drs. Danya Khoujah and Wendy Chang discuss acute radiation sickness and ocular foreign bodies. As always, you'll also hear about the hot topics covered in the regular features, including recurrent palpitations in a middle-aged man in The Critical ECG, primary adrenal insufficiency in Clinical Pediatrics, Lisfranc injury in Critical Cases in Orthopedics and Trauma, active external rewarming of hypothermic patients in The Critical Procedure, managing patients with acute visual loss in The LLSA Literature Review, abdominal pain in a child after a fall in The Critical Image, acetylcysteine for acetaminophen toxicity in The Drug Box, and carbon monoxide toxicity in The Tox Box.

In this Review Series episode, Blood Associate Editor, Dr. Elisabeth Battinelli discusses the Platelet Heterogeneity with authors Drs. Craig Morrell, Larry Frelinger, and Leo Nicolai.  Find the full review series in volume 146 issue 24 of Blood. 

OpenAI ryster i fundamentet. Sam Altman har udløst decideret CODE RED, mens Google Gemini 3 og Claude buldrer frem og udfordrer ChatGPTs førertrøje. Pengene fosser ud af OpenAI, og alle planer er sat på pause for at få en ny version af ChatGPT ud ad døren. Vi tager også fat i en opsigtsvækkende Flügger-historie. DR afslørede ulovlige leverancer af maling til Rusland - men kort efter begynder Googles AI at påstå det stik modsatte, baseret på ikke-eksisterende artikler fra kenyanske luftfartsmyndigheder og obskure universiteter. Et skoleeksempel på, hvordan statsstøttet desinformation kan smyge sig direkte ind i AI-genererede svar. Hvad siger det om Googles evne til at opdage angreb - og om fremtidens informationskrig? Til sidst vender vi Waymos selvkørende taxier, der har fået... selvtillid. Fra artige skolevogne til biler, der laver ulovlige U-vendinger, kører katte ned og gasser hurtigt op. Er det nødvendigt for at følge menneskers trafikmønstre - eller et tegn på, at autonom transport er ved at blive lige så fejlbarlig som os andre? Vi ringer til Morten Bay i LA for at høre, hvordan det er at leve midt i fremtiden. Værter: Marcel Mirzaei-Fard, tech-analytiker, og Henrik Moltke; DRs techkorrespondent.

CME credits: 1.00 Valid until: 11-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/Hepatic-Encephalopathy-More-Common-Than-You-Think/39786/ This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.

In this episode, I sit down with Dr. Sarah Frampton, who conducts research on, amongst other things, improving how we teach, learn, and organize information using behavior-analytic strategies. We explore her career journey, her research on graphic organizers and the Cover, Copy, Compare (CCC) strategy, and the broader implications for stimulus equivalence, educational technology, and effective teaching. In This Episode, You'll Learn: How Sarah's unconventional path led her from economics and psychology into Applied Behavior Analysis (ABA). Why note-taking and structured learning strategies, like CCC, matter for retaining and applying complex information. How stimulus equivalence principles can enhance learning beyond direct instruction. Insights from Sarah's research combining CCC with graphic organizers, including practical takeaways for educators and learners (see Frampton, Vesely and Jackson, 2025). How visual learning tools and educational technology can improve engagement and retention. Strategies for training learners to use these approaches independently and effectively. Highlights From Our Conversation: Sarah's Path Into ABA Sarah shares how a thesis requirement and a Craigslist job posting led her to ABA, including formative experiences working with Dr. Alice Shillingsburg at the Marcus Autism Center. These experiences sparked her interest in efficient, broadly applicable learning strategies. Why Note-Taking Strategies Matter We discuss the value of graphic organizers and the Cover, Copy, Compare (CCC) strategy: Graphic organizers visually display relationships between concepts. CCC is a structured, active-response method that strengthens memory, similar to flashcards. Sarah emphasizes how behavior-analytic techniques can support higher-order thinking processes often considered "cognitive." CCC and Stimulus Equivalence Sarah walks through stimulus equivalence with clear examples, showing how teaching certain relations can produce broader learning without direct instruction. She also highlights a study where CCC and graphic organizers helped learners prepare for tests—even under intentionally challenging conditions. Graphic Organizers in Action Key findings from Sarah's research: Learners who drew more structured organizers performed better. Teaching organizer use during test conditions did not hinder performance. Visualizing relationships among stimuli predicted task success. Training Learners to Use These Strategies Sarah outlines her training sequence, including pre-tests, video instruction, practice with familiar material, and application to abstract stimuli. A core goal was strategy generalization—ensuring learners could apply CCC to new material independently. Fig. 1 from Frampton, et al. (2025) Fig. 2 from Frampton, et al. (2025) Research Findings Most participants quickly mastered abstract relations and passed post-tests after brief training. Notably, all participants used the CCC strategy—some even more meticulously than required. Educational Technology, Engagement, and Mediation Participants reported the educational technology intervention was easy to use and helpful, contrasting with high dropout rates in similar studies. Sarah also describes how participants naturally used private verbal behavior, such as naming stimuli or creating stories, to aid learning. Visual Learning Tools in ABA We discuss the broader application of visual supports—graphic organizers, flashcards, handwriting—and their role in enhancing learning efficiency for both adults and children with autism. Looking Ahead Sarah previews her upcoming presentation at the Verbal Behavior Conference, covering generative learning and assessment tools. We also explore how collaboration and community can reduce burnout and increase long-term job satisfaction in ABA in the "advice for the newly-minted" segment. Resources & Links Session 287: BiDirectional Naming with Caio Miguel. Session 80: Verbal Behavior and Relational Frame Theory, with David Palmer and Josh Pritchard. Shillingsburg, et al. (2016). A Preliminary Procedure for Teaching Children with Autism to Mand for Social Information. Frampton and Linehan (2024). The effects of a training package to teach note taking on the formation of equivalence classes. Sponsor shoutouts! Office Puzzle: A thriving ABA practice depends on systems that actually support your team, not slow them down. If you've struggled with software that's buggy, hard to navigate, or offers little support when you need it most, you're not alone. That's why so many practices are switching to Office Puzzle. Go to officepuzzle.com/bop to learn more! Frontera. Consider taking a demo of Frontera's Assessment Builder and see how the ethical application of AI technologies can help you serve clients and save you time! Your first assessment report is free. And if you use code BOP25 you'll get an additional five assessments for just $100. So head to fronterahealth.com to check it out! MindBodyBehavior's Certified Health Coach Program. If you're a BCBA looking to use your ABA skills to help people live healthier lifestyles, learn how to do it the right way, with expert instruction, mentoring, and guidance from Sarah Burby. Better still, podcast listeners can save $$$ by using the code BOP10 at check out. Click here to learn more! The 2026 Stone Soup Conference! This is one of the best values in the online conference space. I'm actually going to be one of the speakers at this year's event, along with a great cast of other characters you're probably familiar with. Save on your registration by using promo code PODCAST26! The 2026 Verbal Behavior Conference! Taking place March 26–27, 2026, in Austin, Texas, or livestream and on-demand on BehaviorLive. Presenters will include Drs. Mark Sundberg, Patrick McGreevy, Caio Miguel, Alice Shillingsburg, Sarah Frampton, Andresa De Souza, and Danielle LaFrance will share how Skinner's analysis of verbal behavior can guide the assessment and treatment of generative learning challenges in children with autism and other developmental disabilities. And don't miss the special pre-conference workshop on Wednesday, March 25.

Drs. Jack Cush and Artie Kavanaugh preview the upcoming RNL 2026 meeting in Dallas, TX on February 7 & 8, 2026. Register at RheumNow.Live Below is the program: Saturday, February 7, 2026, 7:50 - 8:00 am Welcome & Introductions Drs. Cush and Kavanaugh 8:00 - 10:00 am POD I - Rheumatoid Arthritis: Achieving Better Outcomes 8:00 – 8:30 am Mortality in RA: A Story of Decline, Delay, or Plateau? Elena Myasoedova, MD 8:30 – 9:00 am The Mucosal Hypothesis of Rheumatoid Arthritis Kristen Demoruelle, MD 9:00 – 9:30 am ILD in RA – Recent Advances Jeffrey Sparks, MD 9:30 – 10:00 am Rheumatoid arthritis Faculty Q&A 10:00 - 10:15 am STEP 1: Placebos in Rheumatology Andreas Kerschbaumer, MD 10:15 -10:30 am STEP 2: Disease Modification in Osteoarthritis Tuhina Neogi, MD PhD 10:30 – 11:05 Break 11:05 - 12:10 pm POD II – Advancing Practice 11:05 – 11:30 am Obesity & Inflammation: Weight Management in Rheumatology Uzma Haque, MD 11:30 - 11:55 am Mitigating risk in Rheum Pts undergoing surgery Susan Goodman, MD 11:55 -12:10 pm Practice Panel Faculty Q&A 12:10 – 1:00pm Lunch 1:00 – 3:00 pm POD III – Decisions in Psoriatic Arthritis 1:00 - 1:30 pm Paradoxical Psoriasis and Strange Reactions Joseph Merola, MD 1:30 - 2:00 pm Why Do Plain X rays in Psoriatic Arthritis Arthur Kavanaugh, MD 2:00 - 2:30 pm IL-23 vs IL-17 inhibitors in PsA Andre Ribero, MD 2:30 - 3:00 pm Past, Present & Future of Gout Robert Terkeltaub, MD 3:00 - 3:30 pm Psoriatic Faculty Q&A 3:30 - 4:05 pm Break 4:05 - 4:20 pm STEP 3: Helicobacter Pylori update Byron Cryer, MD 4:20 - 4:35 pm STEP 4: History of Gout Robert Terkeltaub, MD 4:35 – 5:15 pm Keynote Address: 50 Years of Osteoporosis Michael McClung, MD 5:30 – 7:00 pm Reception Sunday, February 8, 2026 Day TOPIC Speaker 7:50-8:00 am Welcome & Introductions Drs. Cush and Kavanaugh 8:00 - 10:00 am POD IV – Staying Ahead of Spondyloarthritis 8:00 – 8:30 am Diagnosing Axial Spondyloarthritis in 2026 Denis Poddubnyy, MD 8:30 – 9:00 am Spondyloarthritis Complications Jessica Walsh, MD 9:00 – 9:30 am 2026 Advances in Spondyloarthritis Catherine Bakewell, MD 9:30 – 10:00 am Spondyloarthritis Faculty Q&A 10:00 – 10:15 am STEP 5: Asymptomatic Elevation of CK Rojit Agarwal, MD MS 10:15 – 10:30 am STEP 6: Update on Myositis Antibodies Rojit Agarwal, MD MS 10:30 – 11:05 am Break 11:05 – 12:10 am POD V – Highlights in Autoimmune Disease 11:05 - 11:35 am SMILE Study – Hydroxychloroquine in ANA+ Arthralgia Nancy Olsen, MD 11:35 – 12:05 am Sjogren's Treatment Landscape in 2026 Matthew Baker, MD 12:05 - 12:20 pm Autoimmune Faculty Q&A 12:20 – 1:25 pm POD VI - Large & Small Vessel Vasculitis 12:20 – 12:45 pm Embracing Relapses in PMR and GCA Michael Putman, MD 12:45 - 1:10 pm Small vessel vasculitis Clay Cockerell, MD 1:10 - 1:25 pm Vasculitis Faculty Q&A 1:30 pm Adjourn

Drs. Stephanie Logterman from Arnold Palmer Hospital for Children and Tyler McDonald from the University of South Alabama bring you this year's IPOS® 2025 episode. We highlight some of the exciting programming from this year's meeting delve into a few interesting topics in pediatric orthopedics. Special guests include Drs. Rachel Thompson, Michael Vitale, Jennifer Beck, Alex Arkader, Brian Kaufman, Lindley Wall, Jaysson Brooks, Henry Ellis, Wood Sankar, and Derek Kelly. This episode is produced by Tyler McDonald. Music by A.A. Aalto.

Host Dr. Ben Jackson speaks with 2025 Roger A. Mann award paper authors Drs. Rebekah Belayneh and Scott Ellis. They discuss their paper: Enhancing the Progressive Collapsing Foot Deformity (PCFD) Classification System Through the Establishment of Defined Radiographic Cut-Off Threshold Values for the Different Deformity Classes. For additional educational resources, visit AOFAS.org

If you are looking for a new approach for team teaching, this podcast is for you! Often, teaching teams distribute the course content and then function independently to teach and grade their assigned content. Drs. Cori Heier and Kristin Ashley describe their new model for team teaching. Two faculty members are responsible for the lecture component of the class, and a third faculty member creates and facilitates in-class activities (every 15 minutes) for the content.

Many nursing programs have high rates of students who fail or do not complete their program for other reasons. Retention is a problem when nurses are critically needed. This podcast with Drs. Hanwook Yoo, Xuechun Zhou, and Beth Phillips presents the results of a research study that showcases the importance of assessing academic readiness prior to admission to a nursing program. This article is OPEN ACCESS so read and share widely.

Bryan Gee closes out 2025 with a heavyweight final edition of the V Podcast, a full-spectrum selection to take you from the dance to the sofa and back again. This month's episode features new heaters from Bladerunner, Serum, L-Side, Alibi, Clipz and Break, plus lyrical pressure from Riya, DRS, MC Moose, Carasel, and Inja. Also expect classic nods from DJ Die, Krust, Dillinja and Ed Rush & Optical, and that unmistakable V blend of rollers and future fire. Alongside the selections, Bryan catches up with Jumpin Jack Frost to talk about the V Legacy programme – and hands over the decks for a special guest mix packed with timeless gems and signature Frosty flavour. Expect VIPs, dubplates, and a Ram Trilogy remix of Warhead that still hits like a freight train. Thanks for listening in 2025 and we'll be back for more next year. Enjoy! 01. MC Fats & Inja – Good Good Rhythm 2. Think Tonk & DRS – Toppa Top 3. Anile & DRS – Untitled 4. Unknown Artist – Latency Dub 5. Jimi Polo – Better Days (Paul T & Edward Oberon Remix) 6. Bladerunner – Come Again 7. Seba – Olski 8. Bladerunner – Hawk 9. Alibi & Carasel – Slap It Down 10. Alibi – Original Style 11. Crystal Clear – Set It Up 12. Riya & Crystal Clear – Overlook 13. Serum – Club Soda 14. Serum – Finger (VIP) 15. Cloud Lord – Ghost Train (VIP) 16. Alibi – Hardcore (VIP) 17. Alibi – Overactivity 18. Alibi – Alright 19. L-Side – Rhythm Section 20. Zero T & L-Side – Gutter 21. Ed Rush & Optical – Funktion 22. DJ Krust – Not Necessarily a Man 23. Krust – Warhead (Ram Trilogy Remix) 24. DJ Die – Slide Away 25. Dillinja – Unexplored Terrain 26. Paul T & Edward Oberon feat. MC Moose – Future Style 27. DJ Die – Sling Shot 28. Clipz – New Jazz Era 29. L-Side – Bad That 30. Break – Home Girl 31. Jumpin Jack Frost Mix

Host Dr. Joe Patterson sits down with Drs. Michael Sutherland, Bryant Oliphant, and Jennifer Hagen to talk about the American College of Surgeons Committee on Trauma and how orthopedic trauma surgeons can get involved and benefit from the organization in daily practice. Live from the OTA 2025 Annual Meeting. For more information and to become an ACS member, click here. For additional educational resources visit OTA.org  

Dean's Chat hosts, Drs. Jensen and Richey, welcome the American Podiatric Medical Association student representatives from Samuel Merritt University College of Podiatric Medicine. This podcast is sponsored by Bako Diagnostics, a tremendous supporter of podiatric medicine to students, residents, and practitioners alike! Nicholas Vang, Quinton Markett, and Kathryn Maebori, join us to discuss how they discovered podiatric medicine, their shadowing experiences, and things that have surprised them in school. They also discuss things that have inspired them, and a series of "Rapid Fire" questions! They also share "professor shout-outs" and their roles with APMSA! Enjoy this conversation with student leaders! #Podiatry #FootAndAnkle #Residency #MedicalEducation #Surgery #PodiatricMedicine #PreMed #HealthCareCareers #DeansChat

诺里斯有惊无险夺得了自己的第一个F1 WDC，但为何这么多人说水分如此之大？所以我们来讨论下，这个冠军值不值，有多水可以在B站包月充电直接支持节目，周一就收听抢先版比赛合作或加听友群+v guanbing-77，注明意图00:00:00 开场+评分00:03:24 诺里斯夺冠含金量讨论00:14:12 维斯塔潘与皮亚斯特里的表现00:19:19 赛后温馨时刻00:24:10 DRS时代的落幕与数据00:26:49 角田的“防守”00:32:32 勒克莱尔的惊艳表现00:43:03 红黑榜评选00:51:53 SC环节

Development of the craniofacial bones impacts more than just face shape, but airway growth, nervous system regulation, and more.  Chiropractic care can have a profound effect on the baby's ability to have growth that supports their nervous system.  Focusing on creating a system that not only educates parents but builds community to empower parents is the focus of Mighty Milestones.  Ashley Dalidowitz discusses how this system supports families with Katie Oshita in this episode.Podcast Guest: Ashley Dalidowitz is a Boston native and parent-child coach specializing in early childhood development, with a multidisciplinary background in speech-language pathology, literature, and music. A mother of five, Ashley is a strong advocate for the salutogenic model of health and the body's innate capacity to heal.Her personal and professional journey has been deeply shaped by chiropractic care, particularly in addressing complex pediatric concerns such as craniofacial distortions, helmet correction, tethered oral tissues (TOTS), tongue-tie revisions, and neurodevelopmental challenges including speech delays, milestone regression, autism spectrum symptoms, and PANS/PANDAS.Ashley's primary focus is brain health and the integrative approaches that support optimal nervous system function. Her interests span chiropractic care for the developing brain, music and speech therapy, traditional nutritional therapies, EMDR, and German New Medicine. Her goal in teaching this course and life's mission is to empower caregivers in building inner trust and confidence as a child's first teacher and advocate.She is the founder of Mighty Milestones, a developmental milestone support group for expectant parents, caregivers, and families with children from conception through age three. Based in Arden, NC, the group uses It's All in the Head by Drs. Rosen and Watson as a guiding resource for early neurodevelopmental care.  Ashley is available for consultations at theconsciouschildcoach.com. Podcast Host: Katie Oshita, RN, BSN, IBCLC has over 25 years of experience working in Maternal-Infant Medicine.  While Katie sees clients locally in western WA, Katie is also a telehealth lactation consultant believing that clients anywhere in the world deserve the best care possible for their needs.  Being an expert on TOTs, Katie helps families everywhere navigate breastfeeding struggles, especially when related to tongue tie or low supply.  Katie is also passionate about finding the root cause of symptoms, using Functional Medicine practices to help client not just survive, but truly thrive. Email katie@cuddlesandmilk.com or www.cuddlesandmilk.com  

Ran annim! Today, travel medicine specialists Drs. Paul Pottinger & Chris Sanford answer your travel health questions, including:Were children really killed by the COVID vaccine?I'm not vaccinated yet against flu--is it too late now?What is up with bird flu in Washington State?How can I protect myself against ciguatera intoxication?Where do I need Hepatitis A vaccine?E-Bikes: Are they safe?What should I know about gathering mushrooms when I travel?Where can I fly a drone overseas and not get in trouble?We hope you enjoy this podcast! If so, please follow us on the socials @germ.and.worm, subscribe to our RSS feed and share with your friends! We would so appreciate your rating and review to help us grow our audience. And, please visit our website: germandworm.com where you can find all our content and send us your questions and travel health anecdotes. Or, just send us an email: germandworm@gmail.com.Our Disclaimer: The Germ and Worm Podcast is designed to inform, inspire, and entertain. However, this podcast does NOT establish a doctor-patient relationship, and it should NOT replace your conversation with a qualified healthcare professional. Please see one before your next adventure. The opinions in this podcast are Dr. Sanford's & Dr. Pottinger's alone, and do not necessarily represent the opinions of the University of Washington or UW Medicine.

Acabó la temporada de Fórmula 1 y, con ella, el curso del motorsport de 2025. Se resolvió la ecuación de quién sería Campeón del Mundo, que cayó del lado de McLaren, que se lleva los dos campeonatos, y muy especialmente, de Lando Norris. El primer episodio del Podcast Técnica Fórmula 1 se centra en analizar la consecución del Campeonato y el cierre de la temporada. Justo Campeón. Justo, justísimo Campeón del Mundo, Lando Norris. Pues no sólo es el que más puntos ha obtenido, sino también el piloto que más ha crecido esta temporada, superando una montaña de problemas internos, reinventándose y ganándole el Mundial a Max Verstappen, casi nada. Sí, muchos dirán que Max es mejor, ya, yo también lo pienso, lo mismo que Leclerc, Alonso y otros tantos, pero es que este deporte no va de eso. A menudo, nos olvidamos que es un deporte de equipo con una cabeza visible, que es el piloto, y todos tienen que ser los mejores en todo o en casi todo. McLaren fue el mejor equipo en cuanto a coche durante media temporada o quizás dos tercios y Red Bull llegó tarde y por eso han perdido el campeonato. Algunos apuntes sobre la (mínima) diferencia de puntos. En cuanto a la diferencia de dos puntos, qué decir, ¿es obra de Max? No, es obra de McLaren, que con sus errores de última hora estuvo a punto de perder el campeonato, cosa que no se le puede achacar a Norris. Sin los puntos de Catar y Las Vegas, Max estaría muy lejos. No perdamos el contexto. Por otro lado, me encanta sobremanera que Norris haya ganado el campeonato a su estilo, sin ser un gilipollas egocéntrico, después de que todos habíamos dicho (me incluyo) que así no se ganaba el Mundial. Pues toma, ¡zas! en toda la boca, como diría Sheldon Cooper. Ha sido fiel a su filosofía, a sus valores y con eso ha ganado a su estilo (y con un cochazo, claro, si no, es imposible). Eso sí, rollo de GP. Que queréis que os diga: me aburren los petrodólares… El fin de una era. Por otro lado, acaba una era en la Fórmula con esta carrera y comienza otra radicalmente distinta: adiós al DRS, a la recuperación de energía calorífica, al efecto suelo, a la normativa aerodinámica, adiós a Tsunoda, a Sauber, etc. y, por supuesto, muchos holas que analizaremos en próximos programas. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with two thoracic oncologists practicing in New Zealand—Dr. Laird Cameron from Auckland Hospital and Dr. Annie Wong from the University of Otago—about the unique challenges and approaches to lung cancer care in their island nation of 5.4 million people. The conversation explores New Zealand's healthcare coverage system, patient population characteristics including smoking rates, the current state of lung cancer screening programs, and how molecular testing is conducted for non-small cell lung cancer patients. Drs. Cameron and Wong discuss access to targeted therapies and immunotherapy, the drug approval process in New Zealand, cultural considerations and health disparities affecting lung cancer treatment, and the clinical research infrastructure available in the country. This global perspective highlights how IASLC members face different regional challenges while working toward common goals in advancing lung cancer care.

Jornalismo e reflexões sobre a Fórmula 1. Para apoiar o nosso projeto, basta se tornar membro do canal e curtir as premiações: https://www.youtube.com/channel/UCXeOto3gOwQiUuFPZOQiXLA/join   Conheça também a Noovamais: mais do que uma corretora, uma revolução no mercado de seguros e financiamentos! Acesse www.noovamais.com.br e confira também no Insta @NoovaMais    Se preferir um formato diferente de Apoio ao nosso canal, confira as facilidades do http://www.apoia.se/cafecomvelocidade para ajudar o Café a crescer e se manter no ar.   E se você curte a agilidade e rapidez do PIX, você pode se tornar apoiador através da chave cafecomvelocidade@gmail.com (este também é o nosso endereço para contato)   APOIANDO O CAFÉ VOCÊ RECEBE: Faixa Café com Leite - Acesso a um grupo exclusivo de membros do canal no whatsapp Faixa Capuccino - O mesmo benefício + acesso a LIVES Exclusivas toda terça-feira pós GP de Fórmula 1 Faixa Extra Forte - Os mesmos benefícios + concorre em sorteios de assinaturas da F1TV até o FINAL DE 2026 ! Faixa Premium - Os mesmos benefícios + concorre também a miniaturas de F1, acesso ao grupo Premium, pode PARTICIPAR das LIVES Exclusivas  e concorre a ingressos para o GP do Brasil de F1 de 2026 em Interlagos !   Não deixe de nos seguir no X / Twitter (@cafevelocidade) e no Instagram (@cafe_com_velocidade)  Siga nossa equipe no X / Twitter: @ricardobunnyman, @brunoaleixo80 e @camposfb   #formula1  #f1 #f12025 #abudhabigp #abudhabigrandprix  #abudhabi #gpabudhabi #qatargp  #qatargrandprix #gpqatar  #lasvegasgp #lasvegasgrandprix #lasvegas #braziliangp #saopaulogp #interlagos #gpdobrasil #brazil #mexicogp #méxico #gpmexico #gpdomexico #usgp  #austingp  #singaporegp #singaporegrandprix  #singapore #azerbaijangp #bakugp #gpazerbaijão #italiangp #italiangrandprix #gpitalia #monzacircuit #dutchgp #dutchgrandprix #zandvoort #zandvoortgp #gpholanda  #hungariangp #hungaroring #gphungria   #belgiumgp  #spafrancorchamps #gpbelgica  #britishgp  #britishgrandprix  #british #silverstone #inglaterra   #austriangp  #austria #gpaustria  #canadiangp  #canadiangrandprix #canada #gpcanada  #spanishgp  #spain  #gpdaespanha  #monacogp   #monaco  #gpmonaco  #emiliaromagnagp #imolagp #imola #gpimola  #miamigp #miami #gpmiami  #saudiarabiangp  #saudiarabia #gparabiasaudita  #bahraingp #bahraingrandprix #bahrain #gpbahrain #gpbahrein  #japanesegp #japangp #japão #gpjapão  #chinesegp  #gpchina  #australiangp  #australiangrandprix  #ausgp  #australia  #gpaustralia  #f1testing  #noticiasdaf1 #formulaone  #f1today  #f1tv #f1team  #f1teams  #f1agora  #f1brasil  #preseason2025  #ferrari  #mercedes  #redbull  #redbullracing  #lewishamilton  #maxverstappen  #charlesleclerc  #carlossainz  #fernandoalonso  #mclaren  #landonorris  #oscarpiastri  #georgerussell   #podcast  #podcasts  #podcasting  #automobilismo  #raceweekend  #raceweek  #f12024 #formula12024  #f1news  #f12026 #alpine #alpinef1 #f1motorsport #f1moments #f1movie 0:00 Abertura: a sensação que o GP de Abu Dhabi deixou 12:53 Café debate sobre a TENSÃO na final da Fórmula 1 25:56 Uma rápida análise sobre o DRS que vai deixar a F1 39:20 Análise: a corrida de Verstappen e a "tática" na final 57:31 Por que vice de Verstappen não foi SÓ por Barcelona ? 1:14:43 Análise: resposta de Verstappen sobre razão do vice 1:28:29 Piastri: as lições a aprender sobre a temporada 2025 1:42:25 Lando Norris: Café analisa o novo Campeão Mundial 2:04:29 Impacto das REGRAS da McLaren na disputa do título 2:15:50 Questões sobre Norris, Hamilton, Leclerc e a F1 2026 2:36:18 Questões sobre punição a Tsunoda e + de Abh Dhabi  

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/personalized-antidepressant-choices-for-better-outcomes-in-mdd-10266SummaryEmphasizing a measurement-based, patient-centered model, this is an enduring podcast/webcast designed for psychiatrists who seek to refine their approach to managing major depressive disorder (MDD). Despite an expanding array of pharmacologic options, many patients continue to experience side effects and residual symptoms that undermine adherence and long-term recovery. Led by Drs. Gregory Mattingly and Gerald Maguire, this activity equips clinicians with evidence-based strategies to compare the nuanced risk–benefit profiles of antidepressants and apply them to individualized treatment plans.This podcast was recorded and is being used with permission of the presenters.Learning ObjectivesAssess the risk–benefit profiles of available antidepressants, including their impact on residual symptoms, to optimize treatment decisions for patients with MDDImplement personalized, measurement-based treatment strategies for patients with MDD to address residual symptoms, promote adherence, and improve outcomesThis activity is accredited for CME/CE CreditThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.75 hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

In this episode of Behind the Knife, the minimally invasive surgery (MIS) team dives deep into the evolving field of common bile duct exploration (CBDE). From the historical context of laparoscopic approaches to the latest advances including robotic-assisted techniques, Drs. Shaina Eckhouse, James Jung, Zachary Weitzner, and Joey Lew discuss key evidence shaping modern practice. Listeners will learn about indications and anatomy guiding trans-cystic versus trans-choledochal approaches, practical tips for safe stone clearance, and critical considerations around learning curves and team coordination for robotic procedures. The episode also highlights important studies comparing single-stage laparoscopic CBDE with staged ERCP and cholecystectomy, emphasizing outcomes such as stone clearance, pancreatitis rates, and hospital length of stay. This comprehensive overview is a must-listen for MIS and acute care surgeons interested in optimizing the management of choledocholithiasis and streamlining patient care with minimally invasive techniques. Hosts:  - Shaina Eckhouse, MD, Bariatric Surgery Medical Director and Vice Chair of Clinical Operations, Department of Surgery, Duke University - James Jung, MD, PhD, Assistant Professor of Surgery, Duke University - Zachary Weitzner, MD, Minimally Invasive and Bariatric Surgery Fellow, Duke University, @ZachWeitznerMD - Joey Lew, MD, MFA, Surgical resident PGY-3, Duke University, @lew__actually Learning Goals:  By the end of this episode, listeners will be able to: -  Describe the historical approaches to managing choledocholithiasis, including staged interventions and the evolution toward single-stage laparoscopic common bile duct exploration (CBDE). -  Summarize key clinical evidence comparing CBDE and ERCP, including landmark studies and meta-analyses evaluating outcomes, complications, and trends over time.​ - Distinguish between transcystic and transcholedochal approaches to CBDE, explaining indications, contraindications, and technical nuances for each technique.​ -  Identify appropriate candidates for transcystic exploration based on cystic duct anatomy and stone characteristics.​ - Recognize the impact of newer surgical technologies—such as digital choledochoscopy, Spyglass, and robotic platforms—on CBDE practice, efficiency, and safety.​ - Discuss the importance of multidisciplinary teamwork, preparation, and perioperative planning for successful CBDE, particularly in complex or altered anatomy cases.​​ - Appraise the learning curve and quality of evidence for new CBDE procedures, outlining the need for mentorship, ongoing training, and knowing when to collaborate with GI or hepatopancreaticobiliary (HPB) surgery.​ - Outline approaches and bailout strategies for challenging cases, including patients with surgically altered anatomy and use of adjuncts such as intraoperative cholangiography (IOC), feeding tube placement, and Fanelli stents.​​ - Evaluate safety outcomes and limitations associated with robotic-assisted CBDE and single-stage management, incorporating recent data from population-based studies.​ -  Reflect on strategies for tailoring CBDE techniques to individual patient anatomy, surgeon experience, and available resources, advocating for evidence-based practice and continuous learning. References: -  Giurgiu DI, Margulies DR, Carroll BJ, et al. Laparoscopic Common Bile Duct Exploration: Long-term Outcome. Arch Surg. 1999;134(8):839-844. doi:10.1001/archsurg.134.8.839 https://pubmed.ncbi.nlm.nih.gov/10443806/ -  Lyu Y, Cheng Y, Li T, Cheng B, Jin X. Laparoscopic common bile duct exploration plus cholecystectomy versus endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy for cholecystocholedocholithiasis: a meta-analysis. Surg Endosc. 2019;33(10):3275-3286. doi:10.1007/s00464-018-06613-w https://pubmed.ncbi.nlm.nih.gov/30511313/ - Bekheit M, Smith R, Ramsay G, Soggiu F, Ghazanfar M, Ahmed I. Meta‐analysis of laparoscopic transcystic versus transcholedochal common bile duct exploration for choledocholithiasis. BJS Open. 2019;3(3):242-251. doi:10.1002/bjs5.50132 https://pubmed.ncbi.nlm.nih.gov/31183439/ - Cironi K, Martin MJ. Reclaim the duct! Laparoscopic common bile duct exploration for the acute care surgeon. Trauma Surg Acute Care Open. 2025;10(Suppl 1). doi:10.1136/tsaco-2025-001821 https://pubmed.ncbi.nlm.nih.gov/40255986/ - Zhang C, Cheung DC, Johnson E, et al. Robotic Common Bile Duct Exploration for Choledocholithiasis. JSLS J Soc Laparosc Robot Surg. 2025;29(1):e2024.00075. doi:10.4293/JSLS.2024.00075 https://pubmed.ncbi.nlm.nih.gov/40144383/ - Kalata S, Thumma JR, Norton EC, Dimick JB, Sheetz KH. Comparative Safety of Robotic-Assisted vs Laparoscopic Cholecystectomy. JAMA Surg. 2023;158(12):1303-1310. doi:10.1001/jamasurg.2023.4389 https://pubmed.ncbi.nlm.nih.gov/37728932/ Ad Disclosure: Visit goremedical.com/btkpod to learn more about GORE® SYNECOR Biomaterial, including supporting references and disclaimers for the presented content. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only  Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

When life feels overwhelming, empathy often becomes the very thing our souls are longing for. In this episode, Gem sits down with Bill and Kristi Gaultiere, founders of Soul Shepherding, to explore the healing power of empathy in the Christian life. Drawing from their new book Deeply Loved, they share how true empathy helps us trade self-judgment for grace, comfort emotional wounds, release worry, and walk more closely with Jesus. This conversation offers practical guidance through the Four A’s of Empathy, along with compassionate wisdom for becoming more grounded, present, and emotionally healthy. Whether you’re navigating conflict, longing for deeper relationships, or seeking healing for your soul, this episode invites you into the life-changing reality of being deeply loved. Drs. Bill and Kristi Gaultiere are the founders of Soul Shepherding. With more than thirty years of counseling and ministry experience, Bill and Kristi have guided thousands of people in the journey toward emotional health and intimacy with Jesus. Their new book, Deeply Loved, is a beautiful, life-giving invitation into the kind of empathy that strengthens relationships, raises our emotional intelligence, and leads us back to the heart of Christ. ______________________________________________________ Connect with Gem on Instagram and learn more on the Unhurried Living website and her new book, Hold That Thought: Sorting Through the Voices in Our Heads Learn about PACE: Certificate in Leadership and Soul Care Discover more Christian podcasts at lifeaudio.com and inquire about advertising opportunities at lifeaudio.com/contact-us.

In the October 2025 episode of Critical Decisions in Emergency Medicine, Drs. Danya Khoujah and Wendy Chang discuss managing thermal burns and diabetic ketoacidosis and hyperosmolar state. As always, you'll also hear about the hot topics covered in the regular features, including syncope and a rapid heartbeat in a young man in The Critical ECG, a boy with hip pain in Clinical Pediatrics, calcaneal fracture in Critical Cases in Orthopedics and Trauma, wedge resection for partial nail removal in The Critical Procedure, albuterol-budesonide rescue inhalation for asthma in The LLSA Literature Review, a patient with a change in mental status in The Critical Image, phenobarbital for alcohol withdrawal syndrome in The Drug Box, and paraquat toxicity in The Tox Box.

Drs. Greg Howell and Jim Wibberding interview Gary Kulik about his new book Conscientious Objectors at War: The Vietnam War's Forgotten Medics. The book features several Adventists and you can purchase it here.What?Adventist Pilgrimage Podcast is a monthly podcast focusing on the academic side of Adventist history and hosted by historians Greg Howell and Jim Wibberding. This podcast is a part of the Adventist History_Project.Links:Web http://adventisthistorypodcast.org/Support: https://www.patreon.com/AdventistHistoryPodcastFacebook: https://www.facebook.com/adventisthistorypodcast/Watch: http://youtube.com/c/adventisthistoryOur Other ShowsAdventist History Podcast (with Matthew J. Lucio)Adventist History Extra (Private Podcast for Our Supporters)The Ellen White Podcast (with Michael W. Campbell)

It's December and that can only mean one thing; it's time for finals! Youngsters across this great nation are staying up late, cramming for their exams, and Drs. Tim Slekar and Johnny Lupinacci are joined by Producer Jakob to talk about their memories of finals' past. BustED Pencils: Fully Leaded Education Talk is part of Civic Media. Subscribe to the podcast to be sure not to miss out on a single episode! Go to bustedpencils.com for swag, all of our episodes, and for information on partnering with us! For information on all of the programming across the Civic Media network, head over to https://civicmedia.us/shows. Join the conversation by calling or texting us at 608-557-8577 to leave a message! Guest: Jakob

“Send us a Hey Now!”We went racing for the final time this season with the WDC on the line at the Abu Dhabi GP.It might have been a more intriguing/anxious race rather than exciting but still kept us interested until the very end.We'll review the race as well as the crowning of this years Champion.The flow will be...1) News & SocialAll the best bits from both the sports news out there as well as what caught our eye on the various social channels2) Brian's Video Vault     https://www.youtube.com/watch?v=c_kToRyvDTM. Alex Albon drives Karun Chandhok to the Qatar GP! Sky Sports F1. 4 mins. https://www.youtube.com/watch?v=nqZI2TR766o. Double stacks, difficult starts and more | 2025 Qatar GP F1 Akkodis Race Debrief. Mercedes channel. 11 mins. https://www.youtube.com/watch?v=PjjQI9W5JkY&t=178s&pp=0gcJCSIKAYcqIYzv. Following Max Verstappen's Race Day Like NEVER BEFORE | Behind The Charge. Oracle Red Bull Racing. 10 mins.https://www.youtube.com/watch?v=UYaESNIPNME. Isack Hadjar and Liam Lawson play GeoGuessr BLINDFOLDED. Visa Cash App RB channel. 7 mins. https://www.youtube.com/watch?v=ACATkaiQHtE F1 2025 finale promo (Canal+). French TV teaser trailer for this weekend done in a Star Wars theme. 1 min of TV genius3) Abu Dhabi GP ReviewPractice, Qualy, and the RaceKing of the Pits vs The PitsPitlane PaulCasino Games updateFinal WDC & WCC updatesRob vs Brian final season resultSupport the showWe would love you to join our Discord server so use this invite link to join us https://discord.gg/XCyemDdzGB To sign up to our newsletter then follow this link https://dirty-side-digest.beehiiv.com/subscribeIf you would like to sign up for the 100 Seconds of DRS then drop us an email stating your time zone to dirtysideofthetrack@gmail.comAlso please like, follow, and share our content on Threads, X, BlueSky, Facebook, & Instagram, links to which can be found on our website.One last call to arms is that if you do listen along and like us then first of all thanks, but secondly could we ask that you leave a review and a 5 star rating - please & thanks!If you would like to help the Dirty Side promote the show then we are now on Buy me a coffee where 100% of anything we get will get pumped into advertising the show https://www.buymeacoffee.com/dirtysideofthetrackDirty Side of the Track is hosted on Buzzsprout https://www.buzzsprout.com/

541. Today, we hear from two of our past hosts of the Savvy Psychologist. Dr. Ellen Hendriksen and Dr. Jade Wu. They will tell us what they've been up to and set the stage for exciting weeks ahead for the show. While we work to fill the seat of the amazing Dr. Monica Johnson, Drs. Hendriksen and Wu will deliver mental health wisdom you are used to. Today, they chat about the meaning of a psychologist's work, the biggest challenges in mental health, and what you can look forward to on the show.Find Dr. Ellen Hendriksen on Substack.Find Dr. Jade Wu on her website.Have a mental health question? Email us at psychologist@quickanddirtytips.com.Find Savvy Psychologist on Facebook and Twitter, or subscribe to the newsletter for more psychology tips.Savvy Psychologist is a part of Quick and Dirty Tips.Links: https://quickanddirtytips.com/savvy-psychologisthttps://www.facebook.com/savvypsychologisthttps://twitter.com/qdtsavvypsych  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.